Effectiveness of Foslevodopa/Foscarbidopa in Subgroups of Patients Earlier within Advanced Parkinson’s Disease in an Interim Dataset of ROSSINI (P3-17.005)

Jason Aldred; W H Jost; F Bergquist; Andrew Evans; Sharon Hassin-Baer; Robert Hauser; Tove Henriksen; Irene Malaty; Tiago Mestre; Ramon Rodriguez Cruz; Petra Schwingenschuh; Mihaela Simu; Lars Bergmann; Sarah Caughlin; Mallika Gopalkrishnan; Pavnit Kukreja; Marie O’Meara; Juan Carlos Parra; Megha Shah; Pablo Mir

doi:10.1212/wnl.0000000000216269

Key Points

This research examines the effectiveness of foslevodopa/foscarbidopa in patients with advanced Parkinson’s disease earlier in their treatment journey.
Utilized an interim dataset from ROSSINI
Analyzed real-world evidence from patients with advanced Parkinson’s disease
Foslevodopa/foscarbidopa demonstrated effectiveness among early-stage advanced Parkinson’s disease patients.
Improvement in patient outcomes was noted, supporting use in this subgroup.

Implication

Shows foslevodopa/foscarbidopa effectiveness in advanced Parkinson’s disease, indicating potential benefit for early-stage patients.

Abstract

To present real-world (RW) evidence on foslevodopa/foscarbidopa (LDp/CDp) effectiveness in patients earlier within advanced Parkinson’s disease (aPD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Aldred et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf36efaef96ed7f055f59 https://doi.org/10.1212/wnl.0000000000216269

View Full Paper

Ask AI

Bookmark

Share

Effectiveness of Foslevodopa/Foscarbidopa in Subgroups of Patients Earlier within Advanced Parkinson’s Disease in an Interim Dataset of ROSSINI (P3-17.005)

Key Points

Implication

Abstract

Discussion

Cite This Study

Effectiveness of Foslevodopa/Foscarbidopa in Subgroups of Patients Earlier within Advanced Parkinson’s Disease in an Interim Dataset of ROSSINI (P3-17.005)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading